Qlucore
0.41 SEK
Less than 1K followers
QCORE
First North Stockholm
IT Services
Technology
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-3.94 %
+9.23 %
-5.48 %
-16.87 %
-21.89 %
-24.53 %
-93.37 %
-
-98.52 %
Qlucore develops AI-based software for use in the healthcare sector. The company's precision medicine solutions transform genetic data into decision-making data to create the right treatment for patients. The company's first diagnostic test – for blood cancer in children – has been approved and CE-marked. The company also has tests for lung cancer under development, and is developing the Qlucore Omics Explorer analysis software.
Read moreMarket cap
17.76M SEK
Turnover
-
Revenue
10.21M
EBIT %
-200.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28.5
2026
Annual report '26
9.9
2026
Interim report Q1'27
9.9
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Qlucore Launches AI-based test for Acute Myeloid Leukemia
Interim report 1 May 2025 - 31 January 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools